The Preventive Risk Outreach And Cascade Testing (PROACT)

November 5, 2026 updated by: Jennifer Lee Caswell-Jin, Stanford University

The Preventive Risk Outreach and Cascade Testing (PROACT)

The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.

Study Overview

Detailed Description

The overarching goal of this study is to facilitate cascade genetic testing to reduce the burden of cancer in families with hereditary cancer syndromes (HCS). We will evaluate different versions of a point-of-care cascade genetic testing referral service for probands with recently detected pathogenic or likely pathogenic genetic variants.

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria - Probands

  1. Age ≥ 18 years old.
  2. Known to carry a pathogenic or likely pathogenic variant in a gene included in the 2024 current Color Health Cancer Panel Test.
  3. Have at least one (1) first- or second-degree relative who is living in the United States and has not yet had germline genetic testing.

Exclusion Criteria - Probands

1. Unable to read and write English or Spanish.

Inclusion Criteria - Relatives

  1. Age ≥ 18 years old.
  2. Resides in the United States.

Exclusion Criteria - Relatives

  1. Completed genetic testing by a clinician within the last 5 years that included the pathogenic or likely pathogenic variant.
  2. Not a first- or second-degree relative of the proband.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PROACT Platform - Minimally Facilitated Testing

The Minimally Facilitated testing arm is a simplified version of the PROACT-AI platform, that provides participants with access to low-cost testing only, in addition to standard of care.

This group will receive access to low-cost genetic testing via an email link and an access code.

Experimental: PROACT Platform - AI

The AI-powered arm will provide participants access to low-cost testing via an AI-powered platform as well as provide additional features including genetic education, motivational interviewing, family communication, and complete follow-up surveys.

This group will receive access to low-cost genetic testing via an AI-powered platform that will also provide genetic education, motivational interviewing, and family communication

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm
Time Frame: 6 months

Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm
Time Frame: 6 months

Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm

6 months
Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm
Time Frame: 6 months

Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm

6 months
Proportion of eligible relatives invited by the patient in each study arm
Time Frame: 180 days

Proportion of eligible relatives invited by the patient in each study arm

180 days
Proportion of eligible relatives who join the PROACT program in each study arm
Time Frame: 28 days

Proportion of eligible relatives who join the PROACT program in each study arm

28 days
Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only]
Time Frame: 180 days

Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only]

180 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess Relatives' appraisal of their decision making about genetic testing
Time Frame: 180 days +/- 90 days

Assess Relatives' appraisal of their decision making about genetic testing, as measured by the Decision Quality Scale. The minimum value for the Decision Quality Scale is 7, and the maximum value is 35. A higher score on this scale indicates a better outcome, i.e. a higher score reflects a more positive appraisal of PROACT by relatives regarding their decision-making about genetic testing.

180 days +/- 90 days
Relatives' confidence in their understanding of hereditary cancer risk
Time Frame: 180 days +/- 90 days

To compare enrolled relatives' confidence in their understanding of hereditary cancer risk, using interviews.

180 days +/- 90 days
Compare the proportion of eligible relatives who requested genetic testing in each study arm
Time Frame: 6 months

Using survey responses, compare the proportion of eligible relatives who requested genetic testing within 6 months of enrollment in each study arm, as measured by survey responses.

6 months
Assess Index patients' appraisal of communication with their relatives
Time Frame: 180 days +/- 90 days

Assess Index patients' appraisal of communication with their relatives, as measured by a modified Patient Assessment of Family Communication Scale. The minimum value of the scale is 10, and the maximum value is 50. A higher score, controlling for baseline, indicates a greater improvement in the patient's assessment of their communication with relatives.

180 days +/- 90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Allison Kurian, MD, Stanford University
  • Principal Investigator: Jennifer Lee Caswell-Jin, MD, Stanford University
  • Principal Investigator: Steven Katz, MD, University of Michigan
  • Principal Investigator: Lawrence An, MD, University of Michigan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2027

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

March 12, 2026

First Submitted That Met QC Criteria

March 12, 2026

First Posted (Actual)

March 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe